Trevena, a US-based specialist drug discovery company, has appointed Robert Ruffolo to its board of directors.
Subscribe to our email newsletter
In January 2009, Dr Ruffolo joined scientific advisory board of Trevena. In addition to that role, Dr Ruffolo has now agreed to become a member of the company’s board of directors.
Dr Ruffolo is a retired president of R&D at Wyeth Pharmaceuticals. Dr Ruffolo also spent 17 years at SmithKline Beecham (now GlaxoSmithKline) and six years at Lilly Research Laboratories.
Dr Ruffolo has received his BS degree in pharmacy, and his PhD degree in pharmacology, both from The Ohio State University.
Maxine Gowen, president and CEO of Trevena, said: “We are delighted to welcome Dr Ruffolo onto our board, where his deep insight and vast experience will help to drive our company forward.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.